Article

Sirt1 enzymatic activity is required for cartilage homeostasis in vivo.

Cartilage Biology and Orthopedic Branch National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH50 South Drive, Bethesda Maryland 20892. .
Arthritis & Rheumatology (Impact Factor: 7.87). 01/2013; 65(1). DOI: 10.1002/art.37750
Source: PubMed

ABSTRACT OBJECTIVE: We and others previously demonstrated that Sirt1 regulates apoptosis and cartilage-specific gene expression in human chondrocytes and mouse models. To determine if Sirt1 enzymatic activity plays a protective role in cartilage homeostasis in vivo, we investigated mice carrying sirt1 mutations to characterize their cartilage. METHOD: Articular cartilage was harvested from 5- and 6-month-old mice paws and knees, homozygous for wild type or sirt1(tm2.1Mcby) (sirt1(y/y) ), an allele carrying a point mutation that encodes a Sirt1 protein with no enzymatic activity. Mice aged 2 days and 6/7 days were also examinated. Joint cartilage was processed for histologic examination or biochemical analyses of chondrocyte cultures. RESULTS: We found that articular cartilage tissue sections from sirt1(y/y) mice, up to 6 months of age, contained reduced levels of type 2 collagen, aggrecan, and glycosaminoglycan. In contrast, protein levels of MMP-8, MMP-9, and MMP-13 were elevated in the sirt1(y/y) mice cartilage. Additional results showed elevated chondrocyte apoptosis in Sirt1 mutant mice as compared to wild type littermates. In line with these observations, PTP1b (protein tyrosine phosphatase b) was elevated in the sirt1(y/y) mice. CONCLUSION: Our in vivo findings from this animal model demonstrated that mice with defective Sirt1 also had defective cartilage with elevated rates of cartilage degradation with age. Hence, normal cartilage homeostasis requires enzymatically active Sirt1 protein. © 2012 American College of Rheumatology.

Download full-text

Full-text

Available from: Mona Dvir-Ginzberg, Mar 23, 2015
0 Followers
 · 
133 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Osteoarthritis (OA) is a destructive joint disease in which the initiation may be attributed to direct injury and mechanical disruption of joint tissues, but the progressive changes are dependent on active cell-mediated processes that can be observed or inferred during the generally long time-course of the disease. Based on clinical observations and experimental studies, it is now recognized a that it is possible for individual patients to exhibit common sets of symptoms and structural abnormalities due to distinct pathophysiological pathways that act independently or in combination. Recent research that has focused on the underlying mechanisms involving biochemical cross talk among the cartilage, synovium, bone, and other joint tissues within a background of poorly characterized genetic factors will be addressed in this review. Copyright © 2015. Published by Elsevier Ltd.
    Current Opinion in Pharmacology 04/2015; 22:51-63. DOI:10.1016/j.coph.2015.03.004 · 4.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic, low-grade inflammation in osteoarthritis (OA) contributes to symptoms and disease progression. Effective disease-modifying OA therapies are lacking, but better understanding inflammatory pathophysiology in OA could lead to transformative therapy. Networks of diverse innate inflammatory danger signals, including complement and alarmins, are activated in OA. Through inflammatory mediators, biomechanical injury and oxidative stress compromise the viability of chondrocytes, reprogramming them to hypertrophic differentiation and proinflammatory and pro-catabolic responses. Integral to this reprogramming are 'switching' pathways in transcriptional networks, other than the well-characterized effects of NFκB and mitogen-activated protein kinase signalling; HIF-2α transcriptional signalling and ZIP8-mediated Zn(2+) uptake, with downstream MTF1 transcriptional signalling, have been implicated but further validation is required. Permissive factors, including impaired bioenergetics via altered mitochondrial function and decreased activity of bioenergy sensors, interact with molecular inflammatory responses and proteostasis mechanisms such as the unfolded protein response and autophagy. Bioenergy-sensing by AMPK and SIRT1 provides 'stop signals' for oxidative stress, inflammatory, and matrix catabolic processes in chondrocytes. The complexity of molecular inflammatory processes in OA and the involvement of multiple inflammatory mediators in tissue repair responses, raises daunting questions about how to therapeutically target inflammatory processes and macroscopic inflammation in OA. Bioenergy sensing might provide a pragmatic 'entry point'.
    Nature Reviews Rheumatology 09/2014; DOI:10.1038/nrrheum.2014.162 · 10.25 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Sirtuin 1 (Sirt1) is a nuclear enzyme from the class III histone deacetylases that modulates gene expression and is involved in bone and cartilage remodeling. The goal of our study was to evaluate Sirt1 activity in peripheral blood mononuclear cells in patients with osteoarthritis in comparison with control patients, and to determine the relationship between Sirt1 activity and production of TNFalpha, IL-6 and IL-8 by peripheral blood mononuclear cells after ex vivo treatment with resveratrol, a Sirt1 activator. A prospective study was performed to compare the activity of Sirt1 in patients with primary osteoarthritis of the knee (American College of Rheumatology criteria) with its activity in controls. Peripheral blood mononuclear cells were isolated from peripheral blood, and Sirt1 activity evaluated from cytoplasmic and nuclear compartments using a fluorometric assay. Culture supernatant levels of TNFalpha, IL-6, and IL-8 were quantified before and after resveratrol ex vivo treatment. Nineteen patients with symptomatic knee osteoarthritis (age 64 +/-9 years) and 18 controls (age 54 +/-13 years) were included. No differences were found in cytoplasmic or nuclear Sirt1 activity between patients and controls. After resveratrol treatment, no changes in TNFalpha or IL-8 levels were found, but a significant dose-dependent increase in IL-6 levels was demonstrated in patients with osteoarthritis, but not controls. Sirt1 activity did not correlate with clinical activity (Lequesne's index) or inflammation (erythrocyte sedimentation rate, C-reactive protein). Sirt1 activity (cytoplasmic and nuclear) from peripheral blood mononuclear cells did not differ between patients with osteoarthritis and controls. Ex vivo treatment of peripheral blood mononuclear cells with resveratrol was associated with a dose-dependent increase in IL-6 levels only in patients with osteoarthritis.
    Clinical Epigenetics 07/2013; 5(1):10. DOI:10.1186/1868-7083-5-10 · 6.22 Impact Factor

Similar Publications